Effectiveness and safety of riociguat in patients with sclerosis of the skin

Update Il y a 4 ans
Reference: EUCTR2014-001353-16

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective of this study is to assess the efficacy of riociguat administered 3 times a day (TID) as compared with placebo in terms of change in the mRSS from baseline to Week 52.


Inclusion criteria

  • diffuse cutaneous systemic sclerosis (dcSSc)